Project Summary

Paul Glaser, M.D., Ph.D. (Young Investigator 2002) of University of Kentucky, will study the genetic variation of a major breakdown enzyme (named cytochrome P450 2D6) in children and adolescents which is involved in the breakdown of many antipsychotic and antidepressant medications, including risperidone.  Risperidone is prescribed for Schizophrenia, Conduct Disorder, ADHD, Tic Disorder, and Autism.  Dr. Glaser's preliminary studies have shown that adults without this enzyme are more likely to have side effects.  The study may lead to new physician guidelines that will promote screening of a child's breakdown genetics and thus prevent serious and life-threatening side effects.

Program Area: SCHIZOPHRENIA/PSYCHOTIC DISORDERS\Schizophrenia\Child/Adolescent (Early Onset)

Search Again